Skip to content
{ 2009 06 04 }

Stiefel Laboratories Reaps First Fruits Of Barrier Acquisition With Completion Of Pivotal Phase III Clinical Trial For 200 Mg Hyphanox(TM)

Stiefel Laboratories, Inc. announced the completion and analysis of a pivotal phase III clinical trial for Hyphanox(TM) (itraconazole) tablet. The 200 mg itraconazole tablet formulation was developed using the proprietary Meltrex(R) technology. This trial is the largest randomized controlled clinical study in onychomycosis ever undertaken.

Bookmark and Share
Posted by SkinDoc on Thursday, June 4, 2009, at 8:00 am. Filed under Skin Care News. Tagged , , , , , , . Follow any responses to this post with its comments RSS feed. Both comments and trackbacks are currently closed.